EPS for Clovis Oncology, Inc. (CLVS) Expected At $-1.71

October 14, 2018 - By Pete Kolinski

Clovis Oncology, Inc. (NASDAQ:CLVS) LogoInvestors sentiment increased to 1.17 in Q2 2018. Its up 0.12, from 1.05 in 2018Q1. It is positive, as 33 investors sold Clovis Oncology, Inc. shares while 48 reduced holdings. 25 funds opened positions while 70 raised stakes. 52.83 million shares or 9.43% more from 48.28 million shares in 2018Q1 were reported.
Century Cos reported 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Invesco stated it has 343,101 shares or 0.01% of all its holdings. Geode Capital Mngmt Limited, a Massachusetts-based fund reported 511,954 shares. Voya Investment Management Ltd Com, a Georgia-based fund reported 641,570 shares. 264,926 are owned by Schwab Charles Inv Mgmt. Jefferies Grp Inc Limited Com holds 0.01% or 31,393 shares. Exane Derivatives accumulated 2,100 shares. Amer Intll Group holds 0% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 31,018 shares. Kingdon Cap Lc, a New York-based fund reported 372,988 shares. Utd Svcs Automobile Association stated it has 8,681 shares. 155,006 were reported by Credit Suisse Ag. Hightower Advisors Lc holds 10,870 shares or 0% of its portfolio. Metropolitan Life Insurance New York has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Ubs Asset Management Americas has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). San Francisco Sentry Group (Ca) reported 400 shares.

Analysts expect Clovis Oncology, Inc. (NASDAQ:CLVS) to report $-1.71 EPS on November, 7.They anticipate $0.47 EPS change or 37.90 % from last quarter’s $-1.24 EPS. After having $-1.94 EPS previously, Clovis Oncology, Inc.’s analysts see -11.86 % EPS growth. The stock decreased 4.26% or $1.19 during the last trading session, reaching $26.73. About 1.30M shares traded or 15.54% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 53.53% since October 14, 2017 and is downtrending. It has underperformed by 69.15% the S&P500.

Clovis Oncology, Inc. (NASDAQ:CLVS) Ratings Coverage

Among 2 analysts covering Clovis Oncology (NASDAQ:CLVS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Clovis Oncology had 2 analyst reports since June 10, 2018 according to SRatingsIntel. On Sunday, June 10 the stock rating was maintained by RBC Capital Markets with “Buy”.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $1.41 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

More recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Seekingalpha.com which released: “Clovis Oncology: Some Positives Emerge” on October 03, 2018. Also Streetinsider.com published the news titled: “Pre-Open Movers 10/02: (DTEA) (OMER) (CLVS) Higher; (SFIX) (NBEV) (VNE) Lower (more…)” on October 02, 2018. Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: October 12, 2018 was also an interesting one.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>